The FDA has granted orphan drug status to ACH-4471 from Achillion Pharmaceuticals. The drug is used to treat patients with C3 Glomerulopathy (C3G)

C3G is a devastating renal disease for which there is no approved therapy. There are estimated to be approximately 4,000 C3G patients in the United States, approximately 4,000 in Europe, and more than 1,000 patients with this devastating disease in Japan.